Crossmark

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Crossref DOI link: https://doi.org/10.1136/jitc-2023-006871

Published Online: 2023-07-04

Published Print: 2023-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Altan, Mehmet https://orcid.org/0000-0001-9229-156X
Wang, Yan

Song, Juhee

Welsh, James

Tang, Chad https://orcid.org/0000-0002-5915-1327
Guha-Thakurta, Nandita

Blumenschein, George R

Carter, Brett W

Wefel, Jeffrey S

Ghia, Amol J

Yeboa, Debra N

McAleer, Mary Frances

Chung, Caroline

Woodhouse, Kristina D

McGovern, Susan L

Wang, Chenyang

Kim, Betty Y S

Weinberg, Jeffrey S

Briere, Tina M

Elamin, Yasir Y

Le, Xiuning

Cascone, Tina

Negrao, Marcelo V https://orcid.org/0000-0001-8938-6699
Skoulidis, Ferdinandos

Ferrarotto, Renata

Heymach, John V

Li, Jing
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02696993 at ClinicalTrials.gov

Documents that mention this clinical trial

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
https://doi.org/10.1136/jitc-2023-006871

Whole brain radiation therapy resulting in radionecrosis: a possible link with radiosensitising chemoimmunotherapy
https://doi.org/10.1136/bcr-2023-256758
Funding

Funding for this research was provided by:

Bristol-Myers Squibb ((N/A) Research support for investigator initiated)

NIH/NCI (P30 CA016672)
License Information

License valid from 2023-07-04

Document is current

Any future updates will be listed below